V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005607 | 10008888 | 1.72 | null | Curative (C) | 2018-04-25 | 2018-05-17 | Cyclophosphamide + Dex + Rituximab | null | N | 10394405 | FCR |
| 10005608 | 10003499 | null | null | Palliative (P) | 2019-05-19 | 2019-05-19 | OFATUMUMAB | 02 | N | 10395265 | GEFITINIB |
| 10005609 | 10003499 | 1.71 | null | null | 2018-05-09 | 2018-06-15 | Fluorouracil + Folinic + RT Bossett | N | null | 10395265 | BEP |
| 10005610 | 10003500 | 1.68 | 68.9 | Palliative (P) | 2019-02-09 | 2019-03-08 | Cetuximab + Radiotherapy Load | N | N | 10400059 | CETUXIMAB + RT |
| 10005611 | 10006904 | 1.54 | null | null | 2019-05-04 | 2019-05-26 | CHLVPP | N | N | 10400809 | NIVOLUMAB |
| 10005612 | 10003501 | 1.77 | null | Unknown (U) | 2019-11-07 | 2019-11-18 | Cytarabine low (10to20mg/m2) IV/SC | 2 | null | 10403796 | PAZOPANIB |
| 10005613 | 10006905 | null | null | Curative (C) | 2019-06-23 | 2019-06-23 | IBRUTINIB | N | null | 10404749 | IDELALISIB + RITUXIMAB |
| 10005614 | 10003502 | 1.72 | 75.45 | Curative (C) | 2018-05-17 | 2018-06-07 | BORTEZOMIB + THALIDOMIDE | null | N | 10406757 | FCR |
| 10005615 | 10003503 | 1.65 | 70.8 | Disease modification (D) | null | 2016-09-08 | FEC + DOCETAXEL + TRASTUZUMAB | 02 | N | 10407160 | CARBOPLATIN + DOCETAXEL |
| 10005616 | 10003503 | 1.56 | 66.4 | Palliative (P) | 2019-09-22 | 2019-09-24 | Temozolomide 150mg/m2 | N | N | 10407160 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005617 | 10003504 | 1.7 | 81.9 | Palliative (P) | 2019-04-13 | 2019-04-18 | Cyclophosphamide High Dose | 01 | Y | 10407956 | MITOMYCIN |
| 10005618 | 10003505 | 1.65 | 84.4 | Palliative (P) | 2017-07-01 | 2017-07-11 | Cisplatin + Etoposide + RT | 02 | N | 10408757 | VINBLASTINE |
| 10005619 | 10003506 | null | null | Palliative (P) | 2019-03-12 | 2019-03-12 | OXALIPLATIN + MDG + PANITUMUMAB | N | N | 10411639 | CAPECITABINE + CARBOPLATIN |
| 10005620 | 10003507 | 1.82 | null | Palliative (P) | 2017-11-22 | 2017-12-18 | MELPHALAN | N | Y | 10411988 | IBRUTINIB |
| 10005621 | 10003508 | 1.5 | 58.15 | Palliative (P) | 2016-10-17 | 2018-05-15 | AC | N | N | 10412890 | TRASTUZUMAB |
| 10005622 | 10003509 | 1.73 | 83 | null | 2017-11-13 | 2017-11-29 | Mitomycin Intravesical | 01 | N | 10415958 | CHLORAMBUCIL + RITUXIMAB |
| 10005623 | 10003509 | 1.53 | 73.7 | Curative (C) | 2019-01-22 | 2019-01-25 | IBRUTINIB | N | N | 10415958 | FCR |
| 10005624 | 10003509 | 1.68 | 64 | Curative (C) | 2019-07-25 | 2019-08-02 | Pazopanib | N | N | 10415958 | TRASTUZUMAB |
| 10005625 | 10003510 | 1.6 | 71.3 | Adjuvant (A) | 2019-08-13 | 2019-08-17 | Cyclophosphamide + Docetaxel | N | N | 10450735 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10005626 | 10003511 | 1.69 | 40.2 | Palliative (P) | 2016-05-17 | 2016-05-19 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10457159 | DOXORUBICIN EMBOLISATION |
| 10005627 | 10003511 | 1.83 | 76.7 | Palliative (P) | 2019-11-27 | 2019-12-05 | CETUXIMAB + IRINOTECAN + MDG | 01 | N | 10457159 | OFATUMUMAB |
| 10005628 | 10003512 | 1.63 | 0 | Palliative (P) | 2019-04-28 | 2019-05-14 | Ipilimumab | 02 | N | 10461654 | RCEOP |
| 10005629 | 10003512 | 1.69 | 54.6 | Palliative (P) | 2019-09-23 | 2019-09-23 | HCX (Cape + Cisp + Tras) - Main | 02 | N | 10461654 | PAZOPANIB |
| 10005630 | 10003513 | 1.61 | 72.5 | Not known (9) | 2018-03-14 | 2018-04-14 | Cyclophosphamide + Docetaxel | 02 | N | 10498862 | CYCLOPHOSPHAMIDE |
| 10005631 | 10003513 | 1.71 | 70.5 | Palliative (P) | 2019-03-25 | 2019-04-07 | PMitCEBO | 2 | null | 10498862 | LOPP |
| 10005632 | 10008307 | 1.82 | null | Curative (C) | 2019-07-25 | 2019-08-08 | Sorafenib | 01 | N | 10518166 | CYTARABINE |
| 10005633 | 10003514 | null | 77.6 | Disease modification (D) | 2017-12-02 | 2017-12-21 | Chlorambucil + Pred + Rituximab | N | null | 10519374 | CARBOPLATIN + DOCETAXEL |
| 10005634 | 10003515 | 1.54 | 47 | null | 2017-10-16 | 2017-10-21 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10519411 | DOXORUBICIN + IFOSFAMIDE |
| 10005635 | 10006911 | 0 | 97.9 | Palliative (P) | 2016-04-04 | 2016-05-09 | IPILIMUMAB + NIVOLUMAB | N | N | 10530156 | CHLVPP |
| 10005636 | 10003516 | null | 115.5 | Palliative (P) | 2019-05-03 | 2019-05-06 | CHLVPP | 02 | N | 10531132 | CETUXIMAB + RT |
| 10005637 | 10003517 | 1.76 | 67.2 | Adjuvant (A) | 2018-10-16 | 2018-10-18 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 10531691 | CHLORAMBUCIL + RITUXIMAB |
| 10005638 | 10006912 | 1.73 | 68 | Disease modification (D) | 2016-10-24 | 2016-10-24 | Cladribine (subcut) 5 days | null | N | 10535413 | LANREOTIDE |
| 10005639 | 10006912 | 1.71 | 83.2 | Palliative (P) | 2016-12-21 | 2017-01-04 | TEMOZOLOMIDE | N | N | 10535413 | TUXEDO TRIAL |
| 10005640 | 10003518 | null | 83.2 | Palliative (P) | 2018-06-10 | 2018-06-14 | CISPLATIN + FLUOROURACIL | 99 | null | 10540643 | CAPECITABINE + MITOMYCIN + RT |
| 10005641 | 10003519 | 1.69 | 100 | Curative (C) | 2019-02-28 | 2019-03-01 | ECarboX | 2 | N | 10540829 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |
| 10005642 | 10003520 | null | null | Curative (C) | 2018-11-23 | 2019-01-17 | Chlorambucil + Pred + Rituximab | 02 | N | 10545759 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005643 | 10003520 | 1.75 | 61 | Adjuvant (A) | 2019-12-11 | 2019-12-11 | CLADRIBINE | N | N | 10545759 | NOT MATCHED |
| 10005644 | 10003521 | 1.84 | 86 | null | 2019-12-17 | 2020-01-06 | CHLVPP | N | N | 10559549 | CARBOPLATIN + RT |
| 10005645 | 10006914 | 1.7 | 94 | Curative (C) | 2018-10-04 | 2018-10-05 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10561852 | MITOMYCIN |
| 10005646 | 10003522 | 1.65 | 110.3 | Adjuvant (A) | 2020-02-28 | 2020-03-01 | Cisplatin + Docetaxel +Fluorouracil | 2 | N | 10458958 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005647 | 10003523 | 1.9 | 72.3 | Palliative (P) | 2019-08-22 | 2019-08-22 | Cetuximab + FLUOROURACIL + FOLINIC ACID + OXALIPLATIN | N | null | 10486944 | CARBO + FLUOROURACIL |
| 10005648 | 10003523 | 1.6 | null | Adjuvant (A) | 2018-09-11 | 2018-09-15 | Trastuzumab Subcutaneous | null | N | 10486944 | CAPECITABINE + CARBOPLATIN |
| 10005649 | 10003524 | 1.77 | 78.7 | Adjuvant (A) | 2019-11-07 | 2019-11-07 | INCA TRIAL | N | N | 10549831 | CETUXIMAB |
| 10005650 | 10003525 | 1.7 | 83.6 | Palliative (P) | 2018-09-17 | 2018-09-17 | Cytarabine HD + Methotrexate HD | N | N | 10553313 | FCR |
| 10005651 | 10003526 | 175 | 81.8 | Curative (C) | 2016-12-15 | 2016-12-22 | PEMBROLIZUMAB | N | N | 10036202 | PEMBROLIZUMAB |
| 10005652 | 10003527 | 1.82 | 60.75 | Curative (C) | 2015-05-26 | 2015-07-09 | Docetaxel 100mg/m2 (21 day) | N | N | 10037882 | DOCETAXEL |
| 10005653 | 10003527 | 1.81 | null | Neo-adjuvant (N) | 2014-12-09 | 2015-02-04 | Rituximab | 2 | N | 10037882 | RITUXIMAB |
| 10005654 | 10003527 | 1.64 | 68 | Disease modification (D) | 2016-08-08 | 2016-08-08 | PEMBROLIZUMAB | 2 | N | 10037882 | PEMBROLIZUMAB |
| 10005655 | 10003528 | null | 65.3 | Curative (C) | 2014-10-21 | 2014-10-21 | Paclitaxel 80mg/m2 day 1 8 15 | N | N | 10089744 | PACLITAXEL |
| 10005656 | 10006917 | 1.79 | null | Palliative (P) | 2017-03-01 | 2017-03-22 | CAPECITABINE + OXALIPLATIN | N | N | 10100460 | CAPECITABINE + OXALIPLATIN |